ADGRG2 and medulloblastoma: Due to its differential expression in medulloblastomas, as well as the fact that it is normally only expressed in the epididymis, GPR64 represents a promising candidate for the development of imaging or radiotherapeutic agents that could be potentially efficacious not only in WNT subgroup medulloblastomas, but also Ewing’s sarcoma.